Overview

iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)

Status:
NOT_YET_RECRUITING

Trial end date:
2029-02-28

Target enrollment:

Participant gender:

Summary

The present study aims to evaluate the efficacy and safety of different combinations of oral antidiabetics in patients with inadequate glycemic control on metformin monotherapy.

Phase:

PHASE3

Details

Lead Sponsor:

Eurofarma Laboratorios S.A.

Treatments:

dapagliflozin
Sitagliptin Phosphate